Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
F 61.185 -4.93% -3.18
FATE closed down 0.76 percent on Monday, September 27, 2021, on 89 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical FATE trend table...

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness -4.93%
Lower Bollinger Band Touch Weakness -4.93%
20 DMA Resistance Bearish -11.15%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -11.15%
Multiple of Ten Bearish Other -11.15%
Outside Day Range Expansion -11.15%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -11.18%
NR7 Range Contraction -11.18%
Inside Day Range Contraction -11.18%
20 DMA Resistance Bearish -10.19%
Older End-of-Day Signals for FATE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1 ATR about 3 hours ago
60 Minute Opening Range Breakdown about 3 hours ago
Down 5% about 5 hours ago
Fell Below Lower Bollinger Band about 5 hours ago
Down 3% about 6 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fate Therapeutics, Inc. Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Stem Cells Hematologic Malignancies Hematopoietic Stem Cell Orphan Disease Orphan Diseases Blood Cells Adult Stem Cell Cord Blood Induced Stem Cells Lysosomal Storage Disorder Umbilical Cord Lysosomal Storage Disorders Muscular Dystrophies

Is FATE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 121.1162
52 Week Low 38.02
Average Volume 1,000,720
200-Day Moving Average 85.95
50-Day Moving Average 78.05
20-Day Moving Average 69.34
10-Day Moving Average 67.17
Average True Range 3.96
ADX 23.63
+DI 14.66
-DI 26.34
Chandelier Exit (Long, 3 ATRs) 64.53
Chandelier Exit (Short, 3 ATRs) 74.24
Upper Bollinger Bands 76.12
Lower Bollinger Band 62.56
Percent B (%b) 0.13
BandWidth 19.56
MACD Line -3.30
MACD Signal Line -3.47
MACD Histogram 0.1718
Fundamentals Value
Market Cap 5.62 Billion
Num Shares 87.2 Million
EPS -1.22
Price-to-Earnings (P/E) Ratio -52.67
Price-to-Sales 261.76
Price-to-Book 12.42
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 68.65
Resistance 3 (R3) 68.46 66.83 67.93
Resistance 2 (R2) 66.83 65.74 66.93 67.70
Resistance 1 (R1) 65.60 65.07 64.78 65.79 67.46
Pivot Point 63.97 63.97 63.57 64.07 63.97
Support 1 (S1) 62.74 62.88 61.93 62.93 61.26
Support 2 (S2) 61.11 62.21 61.21 61.02
Support 3 (S3) 59.88 61.11 60.79
Support 4 (S4) 60.07